Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.

CONCLUSIONS: Among Japanese patients with NVAF, treatment with apixaban 5/2.5mg BID was associated with a significantly lower risk of major bleeding and any bleeding when compared to warfarin. Treatment with dabigatran 150/110mg BID or rivaroxaban 15/10mg QD was associated with a significantly lower risk of major bleeding, but not any bleeding than warfarin. The potential benefit of individual NOACs in real-world practice needs to be assessed further. PMID: 28857611 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research